| scholarly article | Q13442814 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC4908823 |
| https://europepmc.org/articles/PMC4908823?pdf=render | ||
| P932 | PMC publication ID | 4908823 |
| P698 | PubMed publication ID | 23271352 |
| P2093 | author name string | Diane C. Bodurka | |
| David A. Iglesias | |||
| P2860 | cites work | The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 |
| Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study | Q27851528 | ||
| Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers | Q28145813 | ||
| Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1 | Q28214401 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma | Q28267816 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. | Q30442540 | ||
| AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma | Q33512169 | ||
| Molecular profiling of endometrial malignancies | Q33757898 | ||
| Genetics of endometrial cancers | Q33781274 | ||
| Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas | Q34291001 | ||
| Treatment of uterine papillary serous carcinoma with paclitaxel | Q34293815 | ||
| Molecular pathology of endometrial hyperplasia and carcinoma | Q34296260 | ||
| Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy | Q34432555 | ||
| Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study | Q35023418 | ||
| Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma | Q35144264 | ||
| Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group | Q35172203 | ||
| Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases | Q35607764 | ||
| Prognostic parameters of endometrial carcinoma | Q35799482 | ||
| Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway | Q35877999 | ||
| Personalized therapy in endometrial cancer: Challenges and opportunities | Q35911350 | ||
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors | Q36042091 | ||
| Fertility-sparing therapy for young women with endometrial cancer | Q36352064 | ||
| Endometrial carcinoma: pathology and genetics. | Q36762023 | ||
| Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant | Q36873098 | ||
| The role of the EGFR signaling in tumor microenvironment. | Q36951215 | ||
| HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer | Q37080967 | ||
| The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas | Q37269747 | ||
| Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints | Q37314941 | ||
| The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies | Q37349623 | ||
| Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer | Q37376100 | ||
| FGFR2 as a molecular target in endometrial cancer | Q37401322 | ||
| A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma | Q37432527 | ||
| Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy | Q37463664 | ||
| Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. | Q37563971 | ||
| Uterine papillary serous carcinoma: patterns of failure and survival. | Q37582977 | ||
| The landscape of EGFR pathways and personalized management of non-small-cell lung cancer | Q37861196 | ||
| Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. | Q38425937 | ||
| PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors | Q39644716 | ||
| In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 | ||
| Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? | Q40170913 | ||
| High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma | Q40345165 | ||
| Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy | Q40554058 | ||
| An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). | Q43284687 | ||
| Trends in endometrial cancer incidence rates in the United States, 1999-2006. | Q45239608 | ||
| Impact of Adjuvant External-Beam Radiation Therapy in Early-Stage Uterine Papillary Serous and Clear Cell Carcinoma | Q45248164 | ||
| Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma | Q46078660 | ||
| Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer | Q50794118 | ||
| Epidemiology of Endometrial Cancer 2 | Q66883440 | ||
| The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways | Q73459314 | ||
| Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival | Q74113674 | ||
| Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway | Q78029669 | ||
| The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma | Q78038994 | ||
| Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma | Q78233264 | ||
| Conservative treatment of early endometrial cancer: preliminary results of a pilot study | Q82261895 | ||
| Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes | Q83135150 | ||
| HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients | Q83367544 | ||
| Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer | Q83787893 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 797-805 | |
| P577 | publication date | 2012-12-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Clinical advances in hematology & oncology : H & O | Q26867024 |
| P1476 | title | Personalized care in uterine cancer | |
| P478 | volume | 10 |
Search more.